Last reviewed · How we verify
Patients
Patients is a Biologic drug developed by Nadia Bouzidi, PhD. It is currently in Phase 2 development.
Patients with advanced or metastatic urothelial carcinoma are being studied in clinical trials, including a Phase 2 study of sitravatinib in combination with PD-(L)1 checkpoint inhibitors. This study is being conducted by Mirati Therapeutics Inc. to evaluate the effectiveness of sitravatinib in treating urothelial carcinoma.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Patients |
|---|---|
| Sponsor | Nadia Bouzidi, PhD |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Assessment of Periprosthetic Bone Mineral Density in Patients Undergoing Total Knee Prosthesis of Different Design (NA)
- Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma (PHASE2)
- The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health. (NA)
- Collection of Blood From Patients With Prostate Cancer
- Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
- A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases (PHASE3)
- The Effect of Continuous Positive Airway Therapy on the Blood Pressure in Sleepy vs Non-sleepy Patients With Obstructive Sleep Apnea
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Patients CI brief — competitive landscape report
- Patients updates RSS · CI watch RSS
- Nadia Bouzidi, PhD portfolio CI
Frequently asked questions about Patients
What is Patients?
Who makes Patients?
What development phase is Patients in?
Related
- Manufacturer: Nadia Bouzidi, PhD — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing